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ORIGINAL RESEARCH
Background: Theophylline is a nonspeciﬁ  c inhibitor of phosphodiesterases that, despite 
exerting bronchodilator and anti-inﬂ  ammatory effects, is a third-line therapy rarely used to 
treat chronic airﬂ  ow limitation. We wished to evaluate the efﬁ  cacy of oral theophylline as 
measured by improvements in trough (pre-dose) or peak (post-dose) FEV1 and FVC in patients 
with clinically stable COPD.
Design: Meta-analysis of randomized, placebo-controlled trials reported as of June 2005 in 
which theophylline was orally administered to stable COPD patients and the functional evalu-
ations included pre- and post-theophylline values for FEV1 and FVC. 
Results: A total of 18 trials were included in the meta-analysis. The weighted mean differences 
(WMD) with 95% conﬁ  dence intervals (95% CI) for improvement over placebo in trough FEV1 
and FVC were 0.108L (0.053–0.163) and 0.186L (0.036–0.336), respectively, while peak FEV1 
and FVC improved by 0.096L (0.044–0.147) and 0.242L (0.11–0.374), respectively.
Conclusions: Treatment with oral theophylline improves both trough and peak FEV1 and 
FVC in clinically stable COPD patients. These results support previously reported beneﬁ  ts of 
theophylline in COPD.
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Introduction
Theophylline is a nonspeciﬁ  c inhibitor of phosphodiesterases. Since the original 
report of its efﬁ  cacy as a bronchodilator, theophylline has been used extensively 
to treat COPD and asthma (Schultze-Werninghaus and Meier-Sydow 1982). More 
recently, the importance of its anti-inﬂ  ammatory properties has been emphasized 
(Barnes 2003; Barnes et al 2005). Although its use in COPD is recommended in the 
GOLD Guidelines (Pauwels et al 2001), oral theophylline is rarely prescribed in the 
Western Hemisphere due to the belief that it is either poorly efﬁ  cacious, unsafe, or 
cumbersome in the outpatient setting.
Most of the randomized, controlled trials of theophylline reported in stable COPD 
patients used a small sample size (Schmidt and Altschuler 1979; Alexander et al 1980; 
Anderson et al 1982; Marvin et al 1983; Mahler et al 1985; Dullinger et al 1986; Guyatt 
et al 1987; Chrystyn et al 1988; Berry et al 1991; Thomas et al 1992, 1995; Nishimura et al 
1993; Fink et al 1994; Newman et al 1994; Shivaram et al 1997; Tsukino et al 1998; Rossi 
et al 2002; Broseghini et al 2005) and there is only one systematic review/meta-analysis of 
the published data (Ram et al 2005). Thus, controversy still exists about its potential risks 
and beneﬁ  ts. In addition, it is unclear whether any putative beneﬁ  ts of oral theophylline in 
COPD would be immediate (ie, improvement in peak pulmonary function after dosing), 
long-term (ie, improvement in trough pulmonary function over time), or both.
We wished to analyze the efﬁ  cacy of oral theophylline in stable COPD patients. 
We conducted meta-analyses of the trough and peak FEV1 and FVC data reported 
and published as of June 2005 from randomized, placebo-controlled trials in which 
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oral theophylline was administered to clinically stable COPD 
patients. To our knowledge, this approach of analyzing the 
effects of theophylline on peak and trough pulmonary func-
tion has not been reported previously. 
Materials and methods
Types of trials and patients
All the trials included involved treatment with oral 
theophylline in a stable COPD population. Only those 
published trials involving patients with stable COPD who 
had pulmonary function tests (PFTs) performed before and 
after administration of theophylline were included. The 
articles were evaluated for comparisons of theophylline 
vs placebo. Speciﬁ  cally, trough and peak FEV1 and FVC 
results were of interest. 
Search for trials
A search of the PubMed database was performed using 
the terms “theophylline + COPD” for English language 
articles published up to and including June 2005. The lit-
erature search was limited to randomized controlled trials 
in humans. The search yielded 66 articles. A review of 
these articles was conducted for trials involving patients 
with stable COPD who had PFTs measured as part of the 
trial. This yielded 17 articles. Of these, 3 did not provide 
either FEV1 or FVC data and were excluded from the 
analysis, and 4 additional papers were active-controlled 
only (ie, were not placebo controlled) and were also ex-
cluded. Additionally, we reviewed a recently published 
meta-analysis (Ram et al 2005). Since the selection criteria 
for inclusion of publications in this meta-analysis were 
similar to our criteria (albeit not identical), additional ar-
ticles cited by Ram and colleagues that were not identiﬁ  ed 
in our PubMed review were also included. This yielded 8 
additional articles. Therefore, a total of 18 trials met the 
criteria for inclusion in our meta-analysis.
Extraction of data used for meta-analysis
Articles were individually reviewed for the following 
PFT results: trough FEV1, trough FVC (pre-dose values), 
peak FEV1, and peak FVC (highest values post-dose). Not 
all articles reported all four of these PFTs and in many 
cases they did not differentiate between trough and peak. 
If any of the four PFT results were reported, the article 
was accepted. In the cases where the authors did not dif-
ferentiate between trough and peak, we determined this 
from the time the last dose of theophylline was taken and 
the time the PFT was done. The data were extracted from 
text, tables, and/or graphs. 
The mean FEV1 (trough and/or peak) and FVC (trough 
and/or peak) in the theophylline group and the placebo group 
were recorded along with the standard deviation. Addition-
ally, the number of patients participating in each group (n) 
was recorded (Table 1).
Statistical analysis
Individual trial data were pooled using meta-analytical tech-
niques. Meta-analyses involving continuous outcomes were 
based on comparisons of means for theophylline vs placebo. 
For continuous variables (such as trough FEV1, trough FVC, 
peak FEV1, and peak FVC), the results of individual studies 
were pooled using ﬁ  xed-effect weighted mean difference 
(WMD) with the corresponding 95% conﬁ  dence interval 
(CI). The WMD is a meta-analytical technique used to 
combine measures on continuous scales, where the mean, 
standard deviation and sample size for each group are known. 
The weight given to each study is determined by the preci-
sion (the inverse of the variance) of its estimate of effect. 
The WMD technique assumes that all of the trials measured 
the outcomes using the same scales. All statistical analyses 
were carried out using Comprehensive Meta-Analysis™ 
Version 2.
Results
Ten studies with 704 patients combined contributed data 
for the analysis of trough FEV1 (Figure 1), which showed 
a signiﬁ  cant improvement for theophylline of 108 mL over 
placebo (WMD 0.108 L; 95% CI=0.05–0.16). Six studies 
with 166 patients combined contributed data for the analy-
sis of trough FVC (Figure 2), which showed a signiﬁ  cant 
improvement of 186 mL over placebo (WMD 0.186 L; 
95% CI=0.04–0.34). Twelve studies with 800 patients 
combined contributed data for the analysis of peak FEV1 
(Figure 3), which showed a signiﬁ  cant improvement of 
96 mL over placebo (WMD 0.096 L; 95% CI=0.04–0.15). 
Ten studies with 358 patients combined contributed data 
for the analysis of peak FVC (Figure 4), which showed a 
signiﬁ  cant improvement of 242 mL over placebo (WMD 
0.242 L; 95% CI=0.11–0.37). For trough and peak FEV1, 
the largest contribution of data (400 patients) was derived 
from a single study (Rossi et al 2002) that showed a sig-
niﬁ  cant improvement over placebo of 90 mL and 80 mL, 
respectively. International Journal of COPD 2006:1(3) 263
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Discussion
Our results show that oral theophylline confers a 
bronchodilator effect as measured by improvements of 
trough and peak FEV1 and FVC in clinically stable COPD 
patients. One limitation of our study that limits the inter-
pretation of these results is that we did not analyze the 
incidence of adverse events reported by the patients who 
received theophylline. However, in a recent meta-analysis 
that reported similar improvements in pulmonary function 
to those we are reporting, preference for theophylline 
was higher than for placebo despite a higher incidence of 
adverse events (Ram et al 2005). 
Our study dissects the improvements in trough and 
peak pulmonary function tests and shows that the ben-
eﬁ  ts of theophylline are immediate (improvements in 
peak values) and also sustained (improvements in trough 
values).
There is debate around the meaning of improvements in 
trough vs peak pulmonary function, but the debate is more 
intense concerning the magnitude of such improvements 
that are clinically meaningful in COPD (Donohue 2004). 
It is generally agreed that for a particular improvement 
to be considered of value it needs to be accompanied by 
clinical improvement. The improvement of 108 mL seen 
in trough (pre-dose) FEV1 and of 186 mL seen in trough 
FVC, as well as the improvements of 96 mL and 242 mL 
in peak (post-dose) FEV1 and FVC, respectively, seem 
comparable to those achieved with other bronchodilators 
commonly used in COPD. For example, data presented 
at different US Food and Drug Administration (FDA) 
Advisory Committee meetings showed that salmeterol 
provoked an improvement of 90 mL in trough FEV1 
and 200 mL in peak FEV1. Salmeterol 50 mg/ﬂ  uticasone 
250 mg combination therapy achieved 164  mL in trough 
Table 1 Characteristics of randomized controlled trials included in the meta-analysis
Author and year   n   Mean    Males/    Theo dose   Treatment   Baseline FEV1
b 
    age or   females   (mg)   duration 
   range
a        
Schmidt and Altschuler 1979   12   30–70   NR
c   800/day   3-month  crossover   1.0 L 
Alexander et al 1980   40   59   40/0   400/day   4-week  crossover   <60%  predicted 
Anderson et al 1982   21   58   17/4   350–700  /day 8-day  crossover   48%  predicted
d 
Marvin et al 1983   15   50–69   15/0   800  /day 10  days   1.0 L 
Mahler et al 1985   12   60   12/0    Titrated to   4-week crossover   1.36 L 
       10–20 mg/L   
Dullinger et al 1986   10   61   NR    Titrated to   1-week crossover   <  1.0 L 
       10–15 mg/L   
Guyatt et al 1987   19   65   19/0    Titrated to   14 days   1.0 L 
       65–100 mmol/L   
Chrystyn et al 1988   33   53–73   30/3    Titrated to   60 days    < 30% predicted 
       5–20 mg/L   
Berry et al 1991   12   63   12/0   750–1000 mg/day   2  days   1.4 L 
Thomas et al 1992   12   63   6/6    Titrated to   2-week crossover   1.1 L 
       10–16.5 mg/L   
Nishimura et al 1993   12   64   11/1   400–600/day   4-week  crossover   0.9 L 
Newman et al 1994   12   62   11/1    Titrated to   4 weeks   1.1 L 
       10–20 μg/ml   
Fink et al 1994   22   68   17/5    Titrated to   4-week crossover   1.0 L 
       >55 μmol/L   
Nishimura et al 1995   24   65   24/0    Titrated to   4-week crossover   0.96 L 
       >10 μg/mL   
Shivaram et al 1997   17   66   NR   400  /day Single  dose   0.77 L 
Tsukino et al 1998   21   65   21/0   600–800/day   3-day  crossover   1.0 L 
Rossi et al 2002   854   63   709/145    Titrated to   12 months   1.37 L 
       8–20 mg/L   
Broseghini et al 2005   13   67   10/3    Titrated to   2-week crossover   1.3 L 
       10–20 μg/mL   
amean of whole study population 
bmean percent predicted in the study population
cnot reported 
dpeak expiratory ﬂ  ow rates International Journal of COPD 2006:1(3) 264
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FEV1 and 281 mL in peak FEV1 (http://www.fda.gov/
ohrms/dockets/ac/02/transcripts/3830T1.htm). Tiotropium 
improved trough FEV1 by 110–130 mL (depending on the 
study) and peak FEV1 by 240–260mL (http://www.fda.
gov/ohrms/dockets/ac/02/transcripts/3890t1.htm). 
An additive beneﬁ  t of comparable magnitude can be seen 
when oral theophylline is used with another bronchodilator 
(Table 2). This additive effect may be different from the 
putative synergistic mechanism proposed by Barnes et al 
(2003) for the effects of inhaled steroids in COPD (Lim et al 
2000; Oliver et al 2001).
In conclusion, it appears that in patients with clinically 
stable COPD, oral theophylline can improve FEV1 and FVC. 
Since blood levels need to be closely monitored and adjusted 
Model Group by
Outcome
Study name Outcome Statistics for each study Sample size Difference in means and 95% CI
Difference Standard  Lower Upper 
in means error Variance limit limit Z-Value p-Value Group-AGroup-B
FEV1TROUGH Berry 1990 FEV1TROUGH 0.270 0.164 0.027 -0.050 0.590 1.651 0.099 12 12
FEV1TROUGH Broseghini 2005 FEV1TROUGH 0.080 0.184 0.034 -0.281 0.441 0.434 0.664 13 13
FEV1TROUGH Fink 1994 FEV1TROUGH 0.050 0.109 0.012 -0.163 0.263 0.460 0.645 22 22
FEV1TROUGH Guyatt 1987 FEV1TROUGH 0.130 0.110 0.012 -0.085 0.345 1.183 0.237 24 24
FEV1TROUGH Mahler 1985 FEV1TROUGH 0.130 0.065 0.004 0.002 0.258 1.986 0.047 12 12
FEV1TROUGH Newman 1994 FEV1TROUGH 0.130 0.171 0.029 -0.206 0.466 0.758 0.448 12 12
FEV1TROUGH Nishimura 1993 FEV1TROUGH 0.100 0.142 0.020 -0.177 0.377 0.706 0.480 12 12
FEV1TROUGH Nishimura 1995 FEV1TROUGH 0.070 0.174 0.030 -0.270 0.410 0.403 0.687 12 12
FEV1TROUGH Rossi 2001 FEV1TROUGH 0.090 0.040 0.002 0.012 0.168 2.250 0.024 200 200
FEV1TROUGH Tsukino 1998 FEV1TROUGH 0.180 0.123 0.015 -0.062 0.422 1.458 0.145 21 21
0 0 0 . 0 3 5 8 . 3 3 6 1 . 0 3 5 0 . 0 1 0 0 . 0 8 2 0 . 0 8 0 1 . 0 H G U O R T 1 V E F d e x i F
0 0 0 . 0 3 5 8 . 3 3 6 1 . 0 3 5 0 . 0 1 0 0 . 0 8 2 0 . 0 8 0 1 . 0 H G U O R T 1 V E F m o d n a R
-1.00 -0.50 0.00 0.50 1.00
Placebo better Theophylline better
Meta-analysis  (WMD): theophylline vs placebo
Comprehensive Meta-Analysis Version 2
Figure 1 Meta-analysis on trough FEV1 showing results favoring theophylline.
Model Group by
Outcome
Study name Outcome Statistics for each study Sample size Difference in means and 95% CI
Difference Standard  Lower Upper 
in means error Variance limit limit Z-Value p-Value Group-AGroup-B
FVCTROUGH Berry 1990 FVCTROUGH 0.370 0.225 0.051 -0.071 0.811 1.643 0.100 12 12
FVCTROUGH Broseghini 2005 FVCTROUGH 0.080 0.247 0.061 -0.404 0.564 0.324 0.746 13 13
FVCTROUGH Fink 1994 FVCTROUGH 0.100 0.153 0.023 -0.200 0.400 0.654 0.513 22 22
FVCTROUGH Mahler 1985 FVCTROUGH 0.180 0.130 0.017 -0.075 0.435 1.386 0.166 12 12
FVCTROUGH Newman 1994 FVCTROUGH 0.300 0.216 0.047 -0.124 0.724 1.388 0.165 12 12
FVCTROUGH Nishimura 1993 FVCTROUGH 0.160 0.300 0.090 -0.429 0.749 0.533 0.594 12 12
5 1 0 . 0 0 3 4 . 2 6 3 3 . 0 6 3 0 . 0 6 0 0 . 0 7 7 0 . 0 6 8 1 . 0 H G U O R T C V F d e x i F
5 1 0 . 0 0 3 4 . 2 6 3 3 . 0 6 3 0 . 0 6 0 0 . 0 7 7 0 . 0 6 8 1 . 0 H G U O R T C V F m o d n a R
-1.00 -0.50 0.00 0.50 1.00
Placebo better Theophylline better
Meta-analysis (WMD): theophylline vs placebo
Comprehensive Meta-Analysis Version 2
Figure 2 Meta-analysis on trough FVC showing results favoring theophylline.
Model Group by
Outcome
Study name Outcome Statistics for each study Sample size Difference in means and 95% CI
Difference Standard  Lower Upper 
in means error Variance limit limit Z-Value p-Value Group-AGroup-B
FEV1PEAK Alexander 1980 FEV1PEAK 0.150 0.115 0.013 -0.076 0.376 1.302 0.193 40 40
FEV1PEAK Anderson 1982 FEV1PEAK 0.120 0.151 0.023 -0.176 0.416 0.795 0.427 17 17
FEV1PEAK Berry 1990 FEV1PEAK 0.270 0.142 0.020 -0.007 0.547 1.907 0.056 12 12
FEV1PEAK Chrystyn 1988 FEV1PEAK 0.080 0.129 0.017 -0.174 0.334 0.618 0.536 33 33
FEV1PEAK Dullinger 1986 FEV1PEAK 0.080 0.072 0.005 -0.061 0.221 1.116 0.264 10 10
FEV1PEAK Marvin 1983 FEV1PEAK 0.080 0.103 0.011 -0.122 0.282 0.778 0.437 15 15
FEV1PEAK Nishimura 1993 FEV1PEAK 0.020 0.142 0.020 -0.257 0.297 0.141 0.888 12 12
FEV1PEAK Rossi 2001 FEV1PEAK 0.080 0.040 0.002 0.002 0.158 2.000 0.046 200 200
FEV1PEAK Schmidt 1997 FEV1PEAK 0.120 0.154 0.024 -0.181 0.421 0.781 0.435 11 11
FEV1PEAK Shivaram 1997 FEV1PEAK 0.069 0.103 0.011 -0.133 0.271 0.671 0.503 17 17
FEV1PEAK Thomas 1992 FEV1PEAK 0.110 0.139 0.019 -0.162 0.382 0.792 0.428 12 12
FEV1PEAK Tsukino 1998 FEV1PEAK 0.190 0.123 0.015 -0.052 0.432 1.539 0.124 21 21
0 0 0 . 0 7 4 6 . 3 7 4 1 . 0 4 4 0 . 0 1 0 0 . 0 6 2 0 . 0 6 9 0 . 0 K A E P 1 V E F d e x i F
0 0 0 . 0 7 4 6 . 3 7 4 1 . 0 4 4 0 . 0 1 0 0 . 0 6 2 0 . 0 6 9 0 . 0 K A E P 1 V E F m o d n a R
-1.00 -0.50 0.00 0.50 1.00
Placebo Better Theophylline Better
Meta-analysis (WMD): theophylline vs placebo
Comprehensive Meta-Analysis Version 2
Figure 3 Meta-analysis on peak FEV1 showing results favoring theophylline.International Journal of COPD 2006:1(3) 265
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to avert serious, even potentially life-threatening side-effects, 
theophylline remains a third choice in the COPD therapeu-
tic armamentarium. It remains to be shown whether safer 
sub-therapeutic doses of oral theophylline can exert any 
clinically meaningful beneﬁ  t in COPD, as recently proposed 
(Barnes 2005). 
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